These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target. Etxabe A; Lara-Castillo MC; Cornet-Masana JM; Banús-Mulet A; Nomdedeu M; Torrente MA; Pratcorona M; Díaz-Beyá M; Esteve J; Risueño RM Leukemia; 2017 Nov; 31(11):2288-2302. PubMed ID: 28193998 [TBL] [Abstract][Full Text] [Related]
4. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells. Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980 [TBL] [Abstract][Full Text] [Related]
5. Towards repositioning of quinacrine for treatment of acute myeloid leukemia - Promising synergies and in vivo effects. Eriksson A; Chantzi E; Fryknäs M; Gullbo J; Nygren P; Gustafsson M; Höglund M; Larsson R Leuk Res; 2017 Dec; 63():41-46. PubMed ID: 29100024 [TBL] [Abstract][Full Text] [Related]
6. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Hassan HT; Zander A Acta Haematol; 1996; 95(3-4):257-62. PubMed ID: 8677752 [TBL] [Abstract][Full Text] [Related]
7. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones. Al-Mawali A; Gillis D; Lewis I J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508 [TBL] [Abstract][Full Text] [Related]
8. Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Liberante FG; Pouryahya T; McMullin MF; Zhang SD; Mills KI Oncotarget; 2016 Feb; 7(6):6609-19. PubMed ID: 26735888 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1. Tian C; You MJ; Yu Y; Zhu L; Zheng G; Zhang Y Tumour Biol; 2016 Jun; 37(6):7461-71. PubMed ID: 26678889 [TBL] [Abstract][Full Text] [Related]
10. Radotinib inhibits acute myeloid leukemia cell proliferation via induction of mitochondrial-dependent apoptosis and CDK inhibitors. Heo SK; Noh EK; Gwon GD; Kim JY; Jo JC; Choi Y; Koh S; Baek JH; Min YJ; Kim H Eur J Pharmacol; 2016 Oct; 789():280-290. PubMed ID: 27477352 [TBL] [Abstract][Full Text] [Related]
11. Defective in vitro growth of primitive hematopoietic cells from pediatric patients with acute myeloid leukemia. Dorantes-Acosta E; Chávez-González A; Santos JI; Medina-Sanson A; Mayani H Pediatr Blood Cancer; 2008 Dec; 51(6):741-6. PubMed ID: 18680148 [TBL] [Abstract][Full Text] [Related]
13. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells. Lu C; Hassan HT Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192 [TBL] [Abstract][Full Text] [Related]
14. XIAP inhibitors induce differentiation and impair clonogenic capacity of acute myeloid leukemia stem cells. Moreno-Martínez D; Nomdedeu M; Lara-Castillo MC; Etxabe A; Pratcorona M; Tesi N; Díaz-Beyá M; Rozman M; Montserrat E; Urbano-Ispizua A; Esteve J; Risueño RM Oncotarget; 2014 Jun; 5(12):4337-46. PubMed ID: 24952669 [TBL] [Abstract][Full Text] [Related]
15. The rarity of ALDH(+) cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients. Hoang VT; Buss EC; Wang W; Hoffmann I; Raffel S; Zepeda-Moreno A; Baran N; Wuchter P; Eckstein V; Trumpp A; Jauch A; Ho AD; Lutz C Int J Cancer; 2015 Aug; 137(3):525-36. PubMed ID: 25545165 [TBL] [Abstract][Full Text] [Related]
16. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models. Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420 [TBL] [Abstract][Full Text] [Related]
17. Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia. De Astis E; Clavio M; Raiola AM; Ghiso A; Guolo F; Minetto P; Galaverna F; Miglino M; Di Grazia C; Ballerini F; Marani C; Pastori G; Mitscheunig L; Cruciani F; Lovera D; Varaldo R; Ghiggi C; Lemoli RM; Bacigalupo A; Gobbi M Ann Hematol; 2014 Dec; 93(12):2011-8. PubMed ID: 24989345 [TBL] [Abstract][Full Text] [Related]
18. Leukemic progenitor cells are susceptible to targeting by stimulated cytotoxic T cells against immunogenic leukemia-associated antigens. Schneider V; Zhang L; Rojewski M; Fekete N; Schrezenmeier H; Erle A; Bullinger L; Hofmann S; Götz M; Döhner K; Ihme S; Döhner H; Buske C; Feuring-Buske M; Greiner J Int J Cancer; 2015 Nov; 137(9):2083-92. PubMed ID: 25912930 [TBL] [Abstract][Full Text] [Related]
19. Hematopoietic Differentiation Is Required for Initiation of Acute Myeloid Leukemia. Ye M; Zhang H; Yang H; Koche R; Staber PB; Cusan M; Levantini E; Welner RS; Bach CS; Zhang J; Krivtsov AV; Armstrong SA; Tenen DG Cell Stem Cell; 2015 Nov; 17(5):611-23. PubMed ID: 26412561 [TBL] [Abstract][Full Text] [Related]
20. Effect of Compound Zhebei Granule () combined with chemotherapy on surface markers of leukemia stem cell in patients with acute myeloid leukemia. Wang J; Lai ZL; Chen XY; Li DY; Zhang YY; Ma W; Chu YT; Shi FQ; Yang L; Hou L Chin J Integr Med; 2016 Jun; 22(6):438-44. PubMed ID: 26666761 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]